Odyssey Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Jun 17, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Jun 17, 2026
ODTX$20.00+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Collaboration revenue | $— | $1,918 |
| Operating expenses: | ||
| Research and development | 32,321 | 38,774 |
| General and administrative | 7,350 | 7,952 |
| Change in fair value of contingent consideration | 109 | (5,648) |
| Total operating expenses | 39,780 | 41,078 |
| Operating loss | (39,780) | (39,160) |
| Other income (expense), net: | ||
| Interest income | 1,708 | 1,156 |
| Interest expense | (10) | (2) |
| Other expense, net | (117) | (289) |
| Total other income, net | 1,581 | 865 |
| Loss before income taxes | (38,199) | (38,295) |
| Income tax provision | 63 | 140 |
| Net loss | $(38,262) | $(38,435) |
| Other comprehensive (loss) income: | ||
| Foreign currency translation adjustment | (306) | 575 |
| Unrealized loss on marketable securities, net of tax | (86) | (10) |
| Total other comprehensive (loss) income | (392) | 565 |
| Comprehensive loss | $(38,654) | $(37,870) |
| Net loss attributable to common stockholders (see Note 16) | (38,262) | (38,435) |
| Net loss per share attributable to common stockholders, basic and diluted | $(6.77) | $(39.37) |
| Weighted-average common stock outstanding, basic and diluted | 5,655,716 | 976,146 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.